IGFBP-4 Antibody (721108) - N-terminal

Western blot shows recombinant human IGFBP-4 N-terminal fragment (10 ng/lane) and recombinant human IGFBP-4 C-terminal fragment (10 ng/lane). PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human IGFBP-4 N-terminal Monoclonal Antibody (Catalog # MAB7110) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for IGFBP-4 N-terminal fragment at approximately 20 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Product Discontinued

IGFBP-4 Antibody (721108) - N-terminal Summary

• Immunogen: synthetic peptide from human IGFBP-4
  Asp148-Met156
  Accession # P22692
• Specificity: Detects human IGFBP4 N-Terminal in direct ELISAs.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: IGFBP4
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.5 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGFBP-4 Antibody (721108) - N-terminal

• BP-4
• HT29-IGFBP
• IBP4insulin-like growth factor-binding protein 4
• IGF-binding protein 4
• IGFBP4
• IGFBP-4
• IGFBP-4IBP-4
• insulin-like growth factor binding protein 4

Background

Human IGF binding protein 4 (IGFBP-4) was isolated from human plasma based on its ability to bind immobilized IGF-I. Human IGFBP-4 cDNA encodes a 258 amino acid (aa) precursor protein with a predicted 21 aa signal peptide that is processed to generate the 237 aa mature human IGFBP-4. The human IGFBP-4 contains a potential N-linked glycosylation site and shares approximately 90% aa sequence identity with both the mouse and rat IGFBP-4. According to the nomenclature of IGFBPs defined at the 4th International Symposium of IGFs (1997, Tokyo), six high-affinity IGF binding proteins (IGFBP-1, -2, -3, -4, -5, -6), and four IGFBP-related proteins (IGFBPr-1, - 2, -3, -4) have been identified. All IGFBPs have a high cysteine content and share conserved cysteine residues that are clustered in the amino‑ and carboxy-terminal third of the molecule. IGFBPs have been shown to either inhibit or enhance the biological activities of IGF, or act in an IGF-independent manner. Post-translational modification of IGFBPs, including phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins for IGF and may indirectly regulate IGF actions. IGFBP-4 can be cleaved at Met156-Lys157.

1. Jones, J. I. and D.R. Clemons (1995) Endocrine Rev. 16:3.
2. Kelly, K.M. et al. (1996) Intl. J. Biochem. Cell Biol. 28:619.
3. Kim, H-S. et al. (1997) Proc. Natl. Acad. Sci. USA 94:12981.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: IGFBP4
• Uniprot:
  • P22692()